Related Experiment Video
Updated: Dec 21, 2025
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
MicroRNAs in Systemic Lupus Erythematosus: a Perspective on the Path from Biological Discoveries to Clinical Practice
Soon-Min Hong1, Can Liu1, Zhihua Yin2
1Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Shandong Middle Road, Shanghai, 200001, China.
Purpose Of Review:
MicroRNAs (miRNAs) play essential roles in immune abnormalities and organ damage of systemic lupus erythematosus (SLE). Current findings have indicated potential clinical applications of miRNAs for combating SLE. Here, we review recent evidence which support the notions that miRNAs can be novel biomarkers and therapeutic agents for SLE.
Recent Findings:
Following years of the studies of the expression patterns of miRNAs in both peripheral blood cells and body fluids, such as plasma and urine, several miRNAs or miRNA combinations have been associated with disease activity and specific organ damage. In depth analysis reveals complex and multiple roles of certain miRNAs in the pathogenesis of SLE. Manipulating miRNA expression shows in vivo therapeutic effects in lupus mouse models. MiRNAs contribute to the immune disorders and organ damage in SLE. MiRNA based biomarkers and therapies have the potential to be viable options for the treatment of SLE.
Insights
MicroRNAs (miRNAs) are key players in systemic lupus erythematosus (SLE) immune issues and organ damage. Research shows miRNAs can serve as novel biomarkers and therapeutic agents for SLE treatment.
Area of Science:
- Immunology
- Molecular Biology
- Genetics
Background:
- MicroRNAs (miRNAs) are implicated in the immune abnormalities and organ damage characteristic of systemic lupus erythematosus (SLE).
- Existing research highlights the potential of miRNAs as therapeutic targets and diagnostic tools for SLE.
Purpose of the Study:
- To review recent evidence on the role of miRNAs in SLE pathogenesis.
- To explore the potential of miRNAs as biomarkers and therapeutic agents for SLE.
Main Methods:
- Review of current scientific literature on miRNA expression in SLE.
- Analysis of studies investigating miRNA roles in SLE pathogenesis and therapeutic interventions.
- Examination of miRNA expression patterns in peripheral blood cells and body fluids (plasma, urine).
Main Results:
- Specific miRNAs and their combinations are associated with SLE disease activity and organ damage.
- Certain miRNAs exhibit complex and multifaceted roles in the pathogenesis of SLE.
- In vivo studies in lupus mouse models demonstrate therapeutic effects of manipulating miRNA expression.
Conclusions:
- MicroRNAs significantly contribute to immune disorders and organ damage in SLE.
- miRNA-based biomarkers show promise for diagnosing and monitoring SLE.
- miRNA-based therapies offer potential new treatment strategies for SLE.
